ホームMCPワークベンチSkills
ホームワークベンチ通知マイページ
llms.txt · MCPガイドプライバシーポリシー · 利用規約 · サポートv1.8.3
  1. ホーム
  2. /反応

Triethylamine → (R)-2-[4-((S)-2-methoxycarbonyl-pyrrolidin-1-yl)-piperidin-1-yl]-1-(4-methyl-2-oxo-2,3-dihydro-benzoxazol-6-ylmethyl)-2-oxo-ethyl 4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carboxylate

HRID 1864623
印刷

反応式

HRID 1864623 の反応式
[NH:1]1[CH2:6][CH2:5][CH:4]([N:7]2[CH2:11][CH2:10][CH2:9][C@H:8]2[C:12]([O:14][CH3:15])=[O:13])[CH2:3][CH2:2]1.[O:16]=[C:17]1[N:23]([CH:24]2[CH2:29][CH2:28][N:27]([C:30]([O:32][C@@H:33]([C:46](O)=[O:47])[CH2:34][C:35]3[CH:44]=[C:43]([CH3:45])[C:38]4[NH:39][C:40](=[O:42])[O:41][C:37]=4[CH:36]=3)=[O:31])[CH2:26][CH2:25]2)[CH2:22][CH2:21][C:20]2[CH:49]=[CH:50][CH:51]=[CH:52][C:19]=2[NH:18]1.CN(C(ON1N=NC2C=CC=CC1=2)=[N+](C)C)C.[B-](F)(F)(F)F.C(N(CC)CC)C>CN(C=O)C>[O:16]=[C:17]1[N:23]([CH:24]2[CH2:25][CH2:26][N:27]([C:30]([O:32][C@H:33]([CH2:34][C:35]3[CH:44]=[C:43]([CH3:45])[C:38]4[NH:39][C:40](=[O:42])[O:41][C:37]=4[CH:36]=3)[C:46]([N:1]3[CH2:2][CH2:3][CH:4]([N:7]4[CH2:11][CH2:10][CH2:9][C@H:8]4[C:12]([O:14][CH3:15])=[O:13])[CH2:5][CH2:6]3)=[O:47])=[O:31])[CH2:28][CH2:29]2)[CH2:22][CH2:21][C:20]2[CH:49]=[CH:50][CH:51]=[CH:52][C:19]=2[NH:18]1
参加物実験手順後処理出典と根拠反応ノート

参加物

6

反応物 4

HCID 8471TriethylamineHCID 2733207O-(Benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborateHCID 44607828(S)-Methyl 1-(piperidin-4-YL)pyrrolidine-2-carboxylateHCID 68608307(R)-1-carboxy-2-(4-methyl-2-oxo-2,3-dihydrobenzoxazol-6-yl)-ethyl 4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carboxylate

生成物 1

HCID 57973478
(R)-2-[4-((S)-2-methoxycarbonyl-pyrrolidin-1-yl)-piperidin-1-yl]-1-(4-methyl-2-oxo-2,3-dihydro-benzoxazol-6-ylmethyl)-2-oxo-ethyl 4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carboxylate

試薬・触媒・溶媒 1

HCID 6228Dimethylformamide溶媒

実験手順

93 mg (0.44 mmol) methyl (S)-1-piperidin-4-yl-pyrrolidine-2-carboxylate were added to a solution of 200 mg (0.39 mmol) (R)-1-carboxy-2-(4-methyl-2-oxo-2,3-dihydrobenzoxazol-6-yl)-ethyl 4-(2-oxo-1,2,4,5,-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carboxylate, 140 mg (0.44 mmol) TBTU and 61 μL (0.44 mmol) triethylamine in 2 mL DMF and the reaction mixture was shaken overnight at RT. The reaction solution was purified by HPLC without working up; the fractions containing the product were concentrated by evaporation and lyophilised.

後処理

  1. customThe reaction solution was purified by HPLC
  2. additionthe fractions containing the product
  3. concentrationwere concentrated by evaporation

出典と根拠

ORDレコード
ord-27d123df24974a7f82b4ff92b3a8453b
出典データセット
uspto-grants-2009_12
DOI
10.6084/m9.figshare.5104873.v1
特許番号
US07625886B2

反応ノート

このページの内容参加物実験手順後処理出典と根拠反応ノート